Presented in part at the 14th European Hematology Association Congress, Berlin, Germany, June 2009, and the 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, December 2009.
Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★
Version of Record online: 10 JAN 2011
©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 11, Issue 2, pages 336–347, February 2011
How to Cite
Reshef, R., Vardhanabhuti, S., Luskin, M. R., Heitjan, D. F., Hadjiliadis, D., Goral, S., Krok, K. L., Goldberg, L. R., Porter, D. L., Stadtmauer, E. A. and Tsai, D. E. (2011), Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder. American Journal of Transplantation, 11: 336–347. doi: 10.1111/j.1600-6143.2010.03387.x
- Issue online: 27 JAN 2011
- Version of Record online: 10 JAN 2011
- Received 12 June 2010, revised 08 November 2010 and accepted for publication 11 November 2010
Figure S1. Detailed description of management and allograft outcome on 67 patients who underwent RI alone as initial therapy for PTLD.
Table S1. Additional clinical findings
|AJT_3387_sm_SuppMat.eps||200211K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.